NSE - Delayed Quote INR

ZIM Laboratories Limited (ZIMLAB.NS)

Compare
97.28
-2.21
(-2.22%)
At close: 3:29:57 PM GMT+5:30
Loading Chart for ZIMLAB.NS
DELL
  • Previous Close 99.49
  • Open 98.11
  • Bid --
  • Ask --
  • Day's Range 96.50 - 100.99
  • 52 Week Range 89.50 - 131.40
  • Volume 102,594
  • Avg. Volume 149,014
  • Market Cap (intraday) 4.745B
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) 30.88
  • EPS (TTM) 3.15
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.

www.zimlab.in

556

Full Time Employees

March 31

Fiscal Year Ends

Recent News: ZIMLAB.NS

View More

Performance Overview: ZIMLAB.NS

Trailing total returns as of 2/13/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

ZIMLAB.NS
9.52%
S&P BSE SENSEX
2.56%

1-Year Return

ZIMLAB.NS
5.09%
S&P BSE SENSEX
6.41%

3-Year Return

ZIMLAB.NS
13.14%
S&P BSE SENSEX
30.93%

5-Year Return

ZIMLAB.NS
13.14%
S&P BSE SENSEX
83.65%

Compare To: ZIMLAB.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZIMLAB.NS

View More

Valuation Measures

As of 2/12/2025
  • Market Cap

    4.85B

  • Enterprise Value

    5.80B

  • Trailing P/E

    31.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.29

  • Price/Book (mrq)

    2.00

  • Enterprise Value/Revenue

    1.54

  • Enterprise Value/EBITDA

    11.75

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.69%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    3.82B

  • Net Income Avi to Common (ttm)

    179.18M

  • Diluted EPS (ttm)

    3.15

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    98.84M

  • Total Debt/Equity (mrq)

    46.82%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: ZIMLAB.NS

View More

People Also Watch